A California-based biotech company is finding a tremendous amount of success on Tuesday after the company announced that Eli ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...

US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

For 2025, Home Depot said it expects total sales growth of 2% year-over-year, reaching $163.98 billion, slightly below the ...

Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches ...

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Wednesday reported a loss of $3.4 million in its fiscal third quarter. On a per-share basis, the San Diego-based company said it had ...